Your session is about to expire
← Back to Search
IONIS-AGT-LRx for Heart Failure (ASTRAAS-HF Trial)
ASTRAAS-HF Trial Summary
This trial is testing a new drug to see if it can lower angiotensinogen levels in people with heart failure.
- Heart Failure
ASTRAAS-HF Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowASTRAAS-HF Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ASTRAAS-HF Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the enrollment period for this experiment currently open?
"Clinicaltrials.gov states that this research initiative, which was launched on June 8th 2021 and later updated on November 23rd 2022, is no longer recruiting patients. That being said, over 700 other clinical trials are still actively seeking volunteers at the present time."
How could patients be affected by the administration of IONIS-AGT-LRx?
"Taking into account the Phase 2 nature of this trial, there is a moderate amount of evidence verifying IONIS-AGT-LRx's safety; thus, our team at Power has assigned it a score of 2."
What is the current scope of this trial's implementation?
"In addition to Michigan Heart in Ypsilanti, Arkansas Cardiology in Little Rock, and Medstar Washington Hospital Center in DC, this trial is accepting patients from other 13 locations."
Is this clinical trial limited to people under 25 years of age or can older individuals also participate?
"This research requires participants to be between 18 and 80 years of age. Alternatively, there are 22 clinical studies specifically targeting those younger than 18 while 690 trials focus on older demographics above the age of 65."
Is enrollment open for this research study?
"This clinical trial requires 72 participants aged between 18 and 80 who have been diagnosed with heart failure. Women must not be pregnant, lactating or potentially able to conceive while men need to either undergo a surgical sterilization process, abstain from sexual relations or use contraception when engaging in intercourse with women of child-bearing potential. Additionally, all subjects should be taking beta-blockers unless contraindicated or not tolerated by the patient's body."
Share this study with friends
Copy Link
Messenger